newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or